ReviewAging clinical and experimental research2025
Late-onset alzheimer's disease, atherosclerosis, and cerebrovascular disease. A complex relationship too often neglected: a narrative review.
Review in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dietary (Poly)phenol Intake, Inflammatory Biomarkers, and Mild Cognitive Impairment in Italian Adults.Antioxidants (Basel, Switzerland) · 2026Article
- Stem Cell-Derived Extracellular Vesicles Ameliorate the Neuron Mitochondrial Damage Induced by ROS-, LPS-Exposure: In Vitro Model of Neuron, Microglia, and Astrocyte Triple Co-Culture.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the 1990s, a long series of preclinical, epidemiological, clinical, and anatomo-pathological studies have questioned the purely "degenerative" origin of Alzheimer's disease (AD), providing growing evidence of a possible "vascular" involvement in the pathogenesis of this type of dementia.Currently, evidence accumulated from preclinical, epidemiological, anatomo-pathological, clinical, neuroimaging, and proteomic studies supports a significant role of cerebral atherosclerosis in the pathogenesis of late-onset sporadic AD (LOAD). It is now well established that cerebral atherosclerosis, through various mechanisms, can promote the deposition of β-amyloid, as well as cause alterations in energy metabolism and neuronal damage.Conversely, β-amyloid can induce not only inflammation and oxidative stress, but also changes in cerebral hemodynamics, pathological angiogenesis, and endothelial dysfunction, thereby contributing to the development of cerebral atherosclerosis.Consistent data suggest that vascular phenomena may precede neurodegenerative ones. In any case, a dangerous vicious cycle is created, in which a clear separation between degenerative and vascular processes is sometimes extremely difficult to establish.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.